Alterations in Cell Motility, Proliferation, and Metabolism in Novel Models of Acquired Temozolomide Resistant Glioblastoma

Abstract Glioblastoma (GBM) is an aggressive and incurable tumor of the brain with limited treatment options. Current first-line standard of care is the DNA alkylating agent temozolomide (TMZ), but this treatment strategy adds only ~4 months to median survival due to the rapid development of resista...

Full description

Saved in:
Bibliographic Details
Main Authors: D. M. Tiek, J. D. Rone, G. T. Graham, E. L. Pannkuk, B. R. Haddad, R. B. Riggins
Format: article
Language:EN
Published: Nature Portfolio 2018
Subjects:
R
Q
Online Access:https://doaj.org/article/d04b39e1ba5c4c6ea68bb0a9360fff81
Tags: Add Tag
No Tags, Be the first to tag this record!